Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03900598 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 226
- Enrollment target
NCT03900598 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 226 participants.
The verdict
NCT03900598, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 226 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Interventions
- DRUG JNJ-67856633
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2019-04-03 |
| Est. Completion | 2025-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03900598
The ClinicalTrials.gov registry entry for NCT03900598 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JNJ-67856633 is the first listed.
NCT03900598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03900598 about?
NCT03900598 is a clinical study titled "A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)". The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
What is the current status of trial NCT03900598?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 226 participants. The study started on 2019-04-03. Estimated completion is 2025-05-22.
What interventions are being tested in trial NCT03900598?
The interventions under investigation include: JNJ-67856633 (DRUG).
Who is sponsoring clinical trial NCT03900598?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.